Regeneron Genetics Center (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics. The primary goal of RGC is to improve patient outcomes by identifying novel drug targets, clinical indications for development programs, and genomic biomarkers for pharmacogenomic applications.

"RGC applies the best and latest technologies in sequencing and analytics to harness the power of human genetics to create game changing new medicines."  
- Aris Baras, Head of RGC

RGC Milestones

2013  
Regeneron sought to further explore the human genetic code and RGC was born. Launched foundational initiative with Geisinger to sequence 100k participants.

2017  
Discovered inhibition of ANGPTL3 gene in humans and mice is associated with decreased levels of all 3 major lipid fractions and protection from atherosclerotic cardiovascular disease.

2018  
Uncovered loss-of-function variant in HSD17B13 gene associated with reduced risk of chronic liver disease. Partnered with UK Biobank to accelerate our research goals.

2020  
Sequenced our 1,000,000th exome – first organization in the world to do so.

2021  
Discovered rare genetic mutations in GPR75 gene associated with protection against obesity.

2022  
Uncovered a novel association between rare mutations in the CIDEB gene and protection from liver damage and disease.

2023  
10-year anniversary of RGC’s founding.

Science-Led

World-class scientists & researchers.

250+ publications authored based on RGC data

1st genome center in the cloud with fully automated analysis pipelines

RGC Collaborations

Global network of collaborator institutions.

130+ collaborations

23 countries

The Database

Largest & most diverse in the world.

~2.3M exomes sequenced and counting

500K+ underrepresented individuals sequenced

Development of Therapeutics

Our mission: genetics to therapeutics, designed for all.

6 genetics medicines programs in the clinic

~30 therapeutics programs started from novel RGC targets or known genes with novel RGC insights

20+ novel genetic targets discovered

50+ novel protective genetics discoveries